N-(1-Cyanoalkyl)-N-hydroxyureas

Camehn, Rainer; Rehse, Klaus

doi:10.1002/(sici)1521-4184(200001)333:1<27::aid-ardp27>3.0.co;2-z

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analogues of HU form NO in vitro in the presence of an Fe3+ porphyrin complex and an oxygen donor (206). HU reacts with deox-Hb, oxy-Hb and metHb, generating nitrosyl-Hb (207).…”

Section: Hydroxyureamentioning

confidence: 99%

Inflammatory targets of therapy in sickle cell disease

Owusu-Ansah

Ihunnah

Walker

et al. 2016

Translational Research

View full text Add to dashboard Cite

Sickle cell disease (SCD) is a monogenic globin disorder characterized by the production of a structurally abnormal hemoglobin (Hb) variant Hb S, which causes severe hemolytic anemia, episodic painful vaso-occlusion and ultimately end-organ damage. The primary disease pathophysiology is intracellular Hb S polymerization and consequent sickling of erythrocytes. It has become evident over several decades that a more complex disease process contributes to the myriad of clinical complications seen in SCD patients with inflammation playing a central role. Drugs targeting specific inflammatory pathways therefore offer an attractive therapeutic strategy to ameliorate many of the clinical events in SCD. In addition they are useful tools to dissecting the molecular and cellular mechanisms that promote individual clinical events, and for developing improved therapeutics to address more challenging clinical dilemmas such as refractoriness to opioids or hyperalgesia. Here, we discuss the prospect of targeting multiple inflammatory pathways implicated in the pathogenesis of SCD with a focus on new therapeutics, striving to link the actions of the anti-inflammatory agents to a defined pathobiology, and specific clinical manifestations of SCD. We also review the anti-inflammatory attributes and the cognate inflammatory targets of hydroxyurea, the only FDA approved drug for SCD.

show abstract

“…Analogues of HU form NO in vitro in the presence of an Fe3+ porphyrin complex and an oxygen donor (206). HU reacts with deox-Hb, oxy-Hb and metHb, generating nitrosyl-Hb (207).…”

Section: Hydroxyureamentioning

confidence: 99%

Inflammatory targets of therapy in sickle cell disease

Owusu-Ansah

Ihunnah

Walker

et al. 2016

Translational Research

View full text Add to dashboard Cite

show abstract

A Practical Way to Prepare Isobutyronitrile Amides through Reactions between Carboxylic Acids and Azobisisobutyronitrile

et al. 2014

View full text Add to dashboard Cite

A practical and efficient synthesis of N‐isobutyronitrile amides has been achieved through the direct condensation of carboxylic acid and azobisisobutyronitrile (AIBN). Carboxylic acids bearing variously substituted phenyl rings and cinnamic or phenylpropiolic acids were employed to furnish both tertiary and secondary isobutyronitrile amides in moderate to high yields. A radical pathway was proposed. The methodology presented here requires no catalysts and additives, and represents the first practical approach to a variety of valuable amides containing the isobutyronitrile structural unit.magnified image

show abstract